TriangleNCT02860286 · REGISTRY CONDITION SEARCH
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2021-04-09
This is a Phase 2, multicenter, open-label, 2-part, single-arm, 2-stage study of tazemetostat 800 mg two times a day (BID) administered orally. Screening of subjects to determine eligibility for the study will be performed within 21 days of the first planned dose of tazemetostat. In Part 1: planned to enroll 12 subjects with relapsed or refractory malignant mesothelioma regardless of BAP1 status will be treated and undergo pharmacokinetics (PK) blood sample collection after a single tazemetostat 800 mg. Part 2 plans to include 55 subjects with BAP1-deficient relapsed or refractory malignant mesothelioma. Treatment with tazemetostat will continue until disease progression, unacceptable toxicity or withdrawal of consent, or termination of the study. Response assessment will be evaluated after 6 weeks of treatment and then every 12 weeks thereafter while on study.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Cmax
Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Tmax
Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): AUC(0-t)
Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): AUC(0-∞)
Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): t1/2
Part 2: To Assess Disease Control Rate (DCR) Defined as Number of Subjects With Complete Response (CR), Partial Response (PR) and Stable Disease (SD)
Incidence of Treatment-emergent Adverse Events as a Measure of Safety and Tolerability
Part 1 and 2: Objective Response Rate (ORR; Complete Response + Partial Response [CR + PR])
Progression-free Survival (PFS)
Part 1 and 2: Overall Survival (OS)
Part 1 and 2: To Evaluate the Duration of Response (DOR) in Subjects With Confirmed CR or PR
Part 1: To Assess Disease Control Rate (DCR) Defined as Number of Subjects With Complete Response (CR), Partial Response (PR) and Stable Disease (SD)
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: 1. Age (at the time of consent) ≥18 years of age 2. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 3. Has a life expectancy of \>3 months 4. Has mesothelioma (pleural, peritoneal, pericardial, tunica vaginalis) of any histology that is relapsed or refractory after treatment with at least one pemetrexed-containing regimen 5. Has a documented local diagnostic pathology of original biopsy confirmed by a Clinical Laboratory Improvement Amendments (CLIA)/College of American Pathologists (CAP) or equivalent laboratory certification 6. Part 2: Molecular evidence of BAP1 loss of function mutation present on local pathology, e.g., lack of nuclear BAP1 staining by immunohistochemistry (IHC) or evidence of loss of function by gene sequencing 7. Has sufficient archival tumor tissue (a minimum of 10 slides or tumor block) available for central retrospective testing of BAP1 status 8. Has all prior treatment (i.e., chemotherapy, immunotherapy, radiotherapy) related clinically significant toxicities resolve to ≤ Grade 1 per CTCAE, version 4.03 or are clinically stable and not clinically significant, at time of enrollment 9. Prior therapy(ies), if applicable, must be completed according to the criteria below prior to first dose of tazemetostat: * Cytotoxic chemotherapy; at least 21 days since last dose * Non-cytotoxic chemotherapy (e.g., small molecule inhibitor); at least 14 days since last dose * Monoclonal antibody; at least three half-lives since the last dose * Non-antibody immunotherapy (e.g., tumor vaccine); at least 42 days since last dose * Radiotherapy, at least 14 days from last local site radiotherapy * Hematopoietic growth factor; at least 14 days from last dose * Investigational drug; 30 days or five half-lives, whichever is longer, from last dose 10. Has measurable disease based on either modified RECIST \[Nowak 2005\] for thoracic disease or RECIST 1.1 elsewhere 11. Has adequate hematologic (bone marrow and coagulation factors), renal, and hepatic function as defined by criteria below: * Hemoglobin ≥9 mg/dL * Platelets ≥100,000/mm3 (≥100 × 109/L) without platelet transfusion for 7 days * ANC ≥1000/mm3 (≥1.0 × 109/L) without growth factor support for 14 days * Coagulation: Prothrombin time (PT) \<1.5 × ULN and partial thromboplastin time (PTT) \<1.5 × ULN * Creatinine \< 2.0 × ULN * Hepatic function: Conjugated bilirubin \<1.5 × ULN and ALT and AST \<3 × ULN 12. Has a QT interval corrected by Fridericia's formula (QTcF) ≤480 msec 13. Willing to provide tissue for translational research 14. Female subjects of childbearing potential must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study drug; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required and subject also should agree to use an adequate method of contraception starting with screening through 30 days after the last dose of study therapy (if sexually active). 15. Male subjects should agree to use condoms starting with the first dose of study therapy through 30 days after the last dose of study therapy if sexually active with a female of childbearing potential Exclusion Criteria: 1. Has had prior exposure to tazemetostat or other inhibitor(s) of enhancer of zeste homologue-2 (EZH2) 2. Has a history of known central nervous system metastasis 3. Has had a prior malignancy other than the malignancies under study Exception: A subject who has been disease-free for 5 years, or a subject with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible. 4. Has had major surgery within 3 weeks prior to enrollment (a percutaneous biopsy, pleural catheter insertion, placement of central venous catheter or other minor procedure are permitted) 5. Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment throughout their time on study 6. Has cardiovascular impairment, history of congestive heart failure greater than NYHA Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months prior to the planned first dose of tazemetostat; or ventricular cardiac arrhythmia requiring medical treatment 7. Is currently taking any prohibited medication(s) 8. Has an active infection requiring systemic treatment 9. Has a congenital or acquired immunodeficiency, including subjects with known history of infection with human immunodeficiency virus (HIV) NOTE: HIV-positive subjects who are taking antiretroviral therapy are ineligible due to potential PK interactions with tazemetostat. 10. Has known history of chronic infection with hepatitis B virus (hepatitis B surface antigen positive) or hepatitis C virus (detectable anti-hepatitis C circulating viral RNA) 11. Has had a deep venous thrombosis (DVT) or pulmonary embolism within the 3 months prior to study enrollment. NOTE: Subjects with a history of a DVT or pulmonary embolism \>3 months prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this study. 12. Is pregnant or breastfeeding.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Oral Tazemetostat 800mg BID
- intervention Names
- Drug: Tazemetostat
- label
- Open-Label Tazemetostat
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Open-Label Tazemetostat
- description
- Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
- name
- Tazemetostat
- other Names
- EPZ-6438
- E7438
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 74
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- To assess the pharmacokinetic (PK) and safety profile of single (Cycle 1 day 1) and repeated doses (Cycle 1 day 2 onwards) of 800 mg tazemetostat administered as 400 mg tablets in subjects with relapsed or refractory malignant mesothelioma regardless of BRCA1 associated protein 1 (BAP1) status.
- measure
- Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Cmax
- time Frame
- Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 12 post-dose
- measure
- Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Tmax
- time Frame
- Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and12 post-dose.
- description
- To assess the pharmacokinetic (PK) and safety profile of single (Cycle 1 day 1) and repeated doses (Cycle 1 day 2 onwards) of 800 mg tazemetostat administered as 400 mg tablets in subjects with relapsed or refractory malignant mesothelioma regardless of BRCA1 associated protein 1 (BAP1) status
- measure
- Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): AUC(0-t)
- time Frame
- Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and12 post-dose.
- description
- Pharmacokinetics profile of tazemetostat and its metabolite (plasma) assessing AUC(0-∞)
- measure
- Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): AUC(0-∞)
- time Frame
- Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 12 post-dose
- description
- Results from assessing the half-life of Tazemetostat and its metabolite shown below
- measure
- Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): t1/2
- time Frame
- Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 12 post-dose
- description
- Overall, the disease control rate (DCR) (calculated as subjects with CR + subjects with PR + subjects with SD at 12 weeks in duration), and the DCR at 24 weeks.
- measure
- Part 2: To Assess Disease Control Rate (DCR) Defined as Number of Subjects With Complete Response (CR), Partial Response (PR) and Stable Disease (SD)
- time Frame
- The patients were assessed for DCR for up to 24 weeks
- measure
- Incidence of Treatment-emergent Adverse Events as a Measure of Safety and Tolerability
- time Frame
- From the first dose of study treatment until the earlier of either 30 days after the discontinuation of study treatment or until the initiation of subsequent anticancer therapy.
- secondary Outcomes
- description
- ORR (confirmed CR+PR) to tazemetostat in subjects with relapsed/refractory malignant mesothelioma using disease-appropriate standardized response criteria (modified RECIST or RECIST 1.1)
- measure
- Part 1 and 2: Objective Response Rate (ORR; Complete Response + Partial Response [CR + PR])
- time Frame
- Assessed every 6 weeks for duration of study participation which is estimated to be 12 months
- description
- Progression-Free Survival is defined as the interval of time between the date of the first dose of study drug and the earliest date of disease progression or death due to any cause. PFS was analyzed and listed for the ITT population. PFS was calculated using the Kaplan-Meier method.
- measure
- Progression-free Survival (PFS)
- time Frame
- The patients were assessed for PFS for up to 24 weeks
- description
- OS was analyzed and listed for the ITT population. Subjects who have not died were censored at the date of last contact which was identified from a visit date, study assessment (physical examination, vital signs, ECOG performance status, electrocardiogram \[ECG\], study drug record, radiological evaluation), AE, medication, or disposition information. OS was calculated using the Kaplan-Meier method. OS at 12 and 24 weeks along with the associated 2-sided 95% CIs were provided. Median OS, first and third quartiles and associated 95% 2-sided CIs were provided.
- measure
- Part 1 and 2: Overall Survival (OS)
- time Frame
- The patients were assessed for PFS for up to 24 weeks
- description
- DOR was calculated for subjects with a confirmed CR or PR. DOR is defined as the time from the date of the initial response (CR/PR) to the date of first documented PD or death due to any cause, whichever occurs first. DOR censoring rules followed those of the PFS analysis defined in the SAP. DOR was analyzed using the Kaplan-Meier methods and the median DOR, first quartile, and third quartile was presented. The associated 2- sided 95% CIs was estimated.
- measure
- Part 1 and 2: To Evaluate the Duration of Response (DOR) in Subjects With Confirmed CR or PR
- time Frame
- Every 6 weeks up to disease progression or start of new anti-cancer therapy assessed for up to 12 months
- description
- Overall, the disease control rate (DCR) (calculated as subjects with CR + subjects with PR + subjects with SD at 12 weeks in duration), and the DCR at 24 weeks.
- measure
- Part 1: To Assess Disease Control Rate (DCR) Defined as Number of Subjects With Complete Response (CR), Partial Response (PR) and Stable Disease (SD)
- time Frame
- The patients were assessed for DCR for up to 24 weeks
Full study description
- brief Summary
- This is a Phase 2, multicenter, open-label, 2-part, single-arm, 2-stage study of tazemetostat 800 mg two times a day (BID) administered orally. Screening of subjects to determine eligibility for the study will be performed within 21 days of the first planned dose of tazemetostat. In Part 1: planned to enroll 12 subjects with relapsed or refractory malignant mesothelioma regardless of BAP1 status will be treated and undergo pharmacokinetics (PK) blood sample collection after a single tazemetostat 800 mg. Part 2 plans to include 55 subjects with BAP1-deficient relapsed or refractory malignant mesothelioma. Treatment with tazemetostat will continue until disease progression, unacceptable toxicity or withdrawal of consent, or termination of the study. Response assessment will be evaluated after 6 weeks of treatment and then every 12 weeks thereafter while on study.
Source references
- references
- citation
- Zauderer MG, Szlosarek PW, Le Moulec S, Popat S, Taylor P, Planchard D, Scherpereel A, Koczywas M, Forster M, Cameron RB, Peikert T, Argon EK, Michaud NR, Szanto A, Yang J, Chen Y, Kansra V, Agarwal S, Fennell DA. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2022 Jun;23(6):758-767. doi: 10.1016/S1470-2045(22)00277-7. Epub 2022 May 16.
- pmid
- 35588752
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-7595559caa2058765b4d
- requested nct id
- NCT02860286
- primary nct id
- NCT02860286
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
- payload sha256
- 1689b3ca0278890acc22d0bbe56fb6bf727a6efee323aa22f76d4508b08024ba
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-7595559caa2058765b4d
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT02860286
- occurrences
- context exact
- NCT02860286
- end
- 11
- exact text
- NCT02860286
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Malignant Mesothelioma
- query disease state id
- ds-malignant-mesothelioma
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-malignant-mesothelioma-000.json
- source file sha256
- 0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
- source json pointer
- /studies/14/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 4a53ae52e91e6c9bf50e42ca3221917a9a8505fca976ec2adf93927d96609f8e
Preserved source evidence · Not medical advice